A placebo-controlled study of pyritinol ('Encephabol') in dementia.
A double-blind, placebo-controlled trial was carried out on 40 patients suffering from moderately advanced dementia. The patients were allocated randomly either pyritinol (800 mg daily) or identical placebo for 3 months. Assessments using a modified Crichton Geriatric Behavioural Rating Scale were made pre-treatment and monthly up to 3 months, and then at follow-up at 6 months. Patients on pyritinol showed significantly higher levels of improvement than did those on placebo. Laboratory tests conducted throughout remained within normal limits for both groups.
D000368:Aged; D000704:Analysis of Variance; D001921:Brain / Q000378:metabolism; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*; D011746:Pyrithioxin / Q000494:pharmacology / Q000627:therapeutic use*
D011725:Pyridines; D011746:Pyrithioxin; D005947:Glucose